@dr_jon_l The study appears to raise questions. 1. “The median time from symptom onset to receipt of study drug was 6 days.” I believe those recommending use of IVM such as @Covid19Critical suggest giving it promptly on onset of symptoms (as is the case with eg Paxlovid). 1/
@dr_jon_l @Covid19Critical 2. My understanding is that proponents recommend that IVM be given in combination with other supplements/meds. Not sure what current recommendations are, but it has never been suggested IVM as standalone. 2/
@dr_jon_l @Covid19Critical 3. I note the failure to separate the vaccinated and non vaccinated group. Would have been interesting to see whether vaccination made any difference in either group. 3/
@dr_jon_l @Covid19Critical 4. No elaboration on the following apparent IVM group benefits (not within the scope of study goal): “The most common serious adverse events were COVID-19 pneumonia (ivermectin [n = 5]; placebo [n = 7]) and venous thromboembolism (ivermectin [n = 1]; placebo [n = 5]).” Why? 4/
@dr_jon_l @Covid19Critical But going back to my first point, the mean time of starting IVM (and low dose) suggest the study never really left the starting gate. But I’m just a grumpy old lawyer. Interested in thoughts of others for & against @PierreKory, @Covid19Critical, @drbeen_medical #ivermectine 6/6
• • •
Missing some Tweet in this thread? You can try to
force a refresh
